The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 24, 2023
Filed:
May. 11, 2021
Sumitomo Pharma Switzerland Gmbh, Basel, CH;
Takeda Pharmaceutical Company Limited, Osaka, JP;
Brendan Mark Johnson, Chapel Hill, NC (US);
Lynn Seely, San Mateo, CA (US);
Paul N. Mudd, Jr., Cary, NC (US);
Susan Wollowitz, Lafayette, CA (US);
Mark Hibberd, Hampshire, GB;
Masataka Tanimoto, Osaka, JP;
Vijaykumar Reddy Rajasekhar, Apple Valley, CA (US);
Mayukh Vasant Sukhatme, Mamaroneck, NY (US);
Sumitomo Pharma Switzerland GmbH, Basel, CH;
Takeda Pharmaceutical Company Limited, Osaka, JP;
Abstract
Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.